Literature DB >> 24899961

Radiation safety issues in y-90 microsphere selective hepatic radioembolization therapy: possible radiation exposure from the patients.

Young-Chul Kim1, Yun-Hwan Kim2, Soon-Ho Uhm3, Yeon Seok Seo3, Eun-Kyung Park1, Sun-Young Oh1, Eugene Jeong1, Sinae Lee1, Jae-Gol Choe1.   

Abstract

PURPOSE: The purpose of this study was to estimate the possible external radiation dose to other individuals from patients treated with Y-90 resin microspheres for unresectable hepatocellular carcinoma.
METHODS: We designed the study prospectively to estimate the possible radiation dose to other individuals from patients who had been treated with Y-90 microspheres for unresectable hepatocellular carcinoma. We estimated the total effective dose equivalent (TEDE) using two methods: 'theoretical' TEDEs according to the administered activity and 'measured' TEDE based on the 'measured' ambient radiation exposure rate. We compared the results from each method to determine when we can release patients from confinement at the earliest time complying with the patient release criteria.
RESULTS: A total of 20 administrations of Y-90 resin microspheres were done in 18 patients. The average administered activity was 1.2 ± 0.77 (0.28-2.97) GBq. The 'theoretical' TEDEs were in the range of 0.8-10 μSv. The 'measured' TEDEs were in the range of 2.31-185 μSv. The measured TEDEs tend to be higher than the theoretical TEDEs. The values of theoretical and measured TEDE were both far less than 1 mSv, the upper limit at which the licensee can release a patient without any written documents.
CONCLUSION: The effective dose equivalent caused by the Y-90 microsphere administered patient is very low. It is safe in terms of radiation safety to the other individuals when Y-90 microsphere radioembolization therapy is done with dose less than 3 GBq. Because the measured TEDE tends to be higher than the theoretical TEDE, it is recommended to use 'measured' TEDE for determining patient release.

Entities:  

Keywords:  Hepatocellular carcinoma; Liver tumor; Radiation safety; Selective hepatic radio-embolization therapy; Y-90 microsphere

Year:  2010        PMID: 24899961      PMCID: PMC4042917          DOI: 10.1007/s13139-010-0047-7

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  17 in total

1.  A new proposal for monitoring patients in nuclear medicine.

Authors:  J Willegaignon; Maria I C Guimarães; Marcelo T Sapienza; Michael G Stabin; Luiz F Malvestiti; Marília Marone; Gian-Maria A A Sordi
Journal:  Health Phys       Date:  2006-12       Impact factor: 1.316

Review 2.  Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction.

Authors:  Riad Salem; Kenneth G Thurston
Journal:  J Vasc Interv Radiol       Date:  2006-10       Impact factor: 3.464

3.  Bremsstrahlung radiation exposure from pure beta-ray emitters.

Authors:  P B Zanzonico; B L Binkert; S J Goldsmith
Journal:  J Nucl Med       Date:  1999-06       Impact factor: 10.057

4.  Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.

Authors:  Carolyn S Hendrix; Cristina de Leon; Robert O Dillman
Journal:  Clin J Oncol Nurs       Date:  2002 May-Jun       Impact factor: 1.027

Review 5.  Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.

Authors:  Henry N Wagner; Gregory A Wiseman; Carol S Marcus; Hani A Nabi; Conrad E Nagle; Darlene M Fink-Bennett; Dominick M Lamonica; Peter S Conti
Journal:  J Nucl Med       Date:  2002-02       Impact factor: 10.057

6.  Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy.

Authors:  J A Siegel
Journal:  J Nucl Med       Date:  1998-08       Impact factor: 10.057

Review 7.  Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres.

Authors:  Seza A Gulec; Jeffry A Siegel
Journal:  J Nucl Med       Date:  2007-11-15       Impact factor: 10.057

Review 8.  Yttrium-90 microspheres: radiation therapy for unresectable liver cancer.

Authors:  Riad Salem; Kenneth G Thurston; Brian I Carr; James E Goin; Jean-Francois H Geschwind
Journal:  J Vasc Interv Radiol       Date:  2002-09       Impact factor: 3.464

9.  Calculating the absorbed dose from radioactive patients: the line-source versus point-source model.

Authors:  Jeffry A Siegel; Carol S Marcus; Richard B Sparks
Journal:  J Nucl Med       Date:  2002-09       Impact factor: 10.057

10.  Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy.

Authors:  V L Gates; J E Carey; J A Siegel; M S Kaminski; R L Wahl
Journal:  J Nucl Med       Date:  1998-07       Impact factor: 10.057

View more
  8 in total

1.  Personnel dose reduction in 90Y microspheres liver-directed radioembolization: from interventional radiology suite to patient ward.

Authors:  Martin Law; K K Wong; W K Tso; Victor Lee; M Y Luk; C C Tong; Ferdinand Chu
Journal:  Br J Radiol       Date:  2016-12-20       Impact factor: 3.039

2.  Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab.

Authors:  Beom-Su Jang; Sang-Myung Lee; Hyung Sub Kim; In Soo Shin; Faezeh Razjouyan; Shutao Wang; Zhengsheng Yao; Ira Pastan; Matthew R Dreher; Chang H Paik
Journal:  Nucl Med Biol       Date:  2011-12-14       Impact factor: 2.408

3.  Nuclear imaging for functional evaluation and theragnosis in liver malignancy and transplantation.

Authors:  Jae Seon Eo; Jin Chul Paeng; Dong Soo Lee
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

Review 4.  Radioembolization for the Treatment of Primary and Metastatic Liver Cancers.

Authors:  Eun Jeong Lee; Hyun Woo Chung; Joon-Hyung Jo; Young So
Journal:  Nucl Med Mol Imaging       Date:  2019-11-08

5.  Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison.

Authors:  Jianghai Zhao; Hui Zhang; Lunshou Wei; Shuping Xie; Zhimin Suo
Journal:  Oncotarget       Date:  2017-02-28

6.  Internal dosimetry for radioembolization therapy with Yttrium-90 microspheres.

Authors:  Maryam Fallahpoor; Mehrshad Abbasi; Ali Asghar Parach; Faraz Kalantari
Journal:  J Appl Clin Med Phys       Date:  2017-01-24       Impact factor: 2.102

Review 7.  Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review.

Authors:  Nicolas Voizard; Milena Cerny; Anis Assad; Jean-Sébastien Billiard; Damien Olivié; Pierre Perreault; Ania Kielar; Richard K G Do; Takeshi Yokoo; Claude B Sirlin; An Tang
Journal:  Insights Imaging       Date:  2019-12-18

Review 8.  Development of Radiotracers for Breast Cancer-The Tumor Microenvironment as an Emerging Target.

Authors:  Amelie Heesch; Jochen Maurer; Elmar Stickeler; Mohsen Beheshti; Felix M Mottaghy; Agnieszka Morgenroth
Journal:  Cells       Date:  2020-10-21       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.